Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
VANCOUVER, BC, Oct. 3, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and Russell 2000 closed the week in the red, underscoring a narrow rally as the quarter turned over. The S&P 500 slipped from its prior week's close despite a strong Friday session. Volatility eased, with the VIX down on the day, while crude oil fell sharply and the 10-year Treasury yield ticked higher. Several companies issued contracts, guidance updates, and acquisition news during the stretch. Active Companies from around the markets with current developments this week include: RTX (NYSE: RTX), Integra LifeSciences Holdings Corporation (Nasdaq: IART), Trilogy Metals Inc. (NYSE American: TMQ), Phillips Edison & Company, Inc. (Nasdaq: PECO), and Axogen, Inc. (Nasdaq: AXGN).
The Dow Jones Industrial Average closed at 51,094.96, up 0.33% on the day but down 1.42% for the week, with an RSI14 of 38.1 signaling a weakening trend. The S&P 500 finished at 7,719.34, up 0.69% on the day though down 0.31% for the week, while the Nasdaq Composite jumped 1.18% on the day to 27,188.02 and gained 0.44% for the week. The Russell 2000 rose 0.97% on the day to 2,833.74 but slipped 0.13% for the week.
The CBOE Volatility Index fell to 15.58, down 0.81 on the day and 0.49 for the week, while the Nasdaq-100 Volatility Index closed at 21.93, down 0.58 on the day but up 1.06 for the week. WTI crude oil dropped 2.48% on the day and 2.19% for the week to $90.57 a barrel, while natural gas rose 1.69% on the day to $3.02 per MMBtu.
Gold eased 0.85% on the day to $4,166.60 an ounce, essentially flat for the week, while silver fell 0.53% on the day and 1.33% for the week to $60.40. Copper gained 1.07% on the day to $6.55 a pound. The US 10-year Treasury yield rose 2 basis points on the day and 8 basis points for the week to 5.26%, and the euro weakened 0.64% on the day against the dollar.
The full report includes the week's key support and resistance levels for each major index along with additional company news and sentiment from the week.
CONTINUED... Read this and more news for RTX (NYSE: RTX), Integra LifeSciences Holdings Corporation (Nasdaq: IART), Trilogy Metals Inc. (NYSE American: TMQ), Phillips Edison & Company, Inc. (Nasdaq: PECO), and Axogen, Inc. (Nasdaq: AXGN) at: https://stockpreachers.com/articles/big-tech-carries-the-tape-while-the-dow-limps-to-friday/
In other industry developments and happenings in the market this week include:
RTX (NYSE: RTX) Raytheon, an RTX business, secured a five-year contract with two additional option years valued up to $24.4 billion for Standard Missile-6 interceptors, aimed at increasing availability of the multi-mission munition for the U.S. Navy.
"SM-6's multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand," said Phil Jasper, Raytheon President. "By continuously investing in our operations and facilities, we are removing constraints and boosting capacity to ensure we deliver this critical capability our sailors depend on."
The company said SM-6 is the only combat-proven weapon capable of anti-air warfare, anti-surface warfare and ballistic missile defense, and has invested in workforce growth, industrial partnerships and automation to support higher output. Read the release.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) Integra LifeSciences provided preliminary third quarter results and updated full-year 2026 guidance, citing continued impact from a July flooding event at its Cincinnati facility. The company expects third quarter revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59.
"Our third quarter results were impacted by the July flooding event at our Cincinnati facility," said Stuart Essig, Chairman and Chief Executive Officer. "Our teams have made significant progress executing recovery plans and supporting customers."
The company updated its full-year 2026 revenue outlook to a range of $1.634 billion to $1.654 billion from $1.654 billion to $1.695 billion, and lowered adjusted EPS guidance to $2.30 to $2.40 from $2.40 to $2.50, while still expecting $190 million to $200 million in operating cash flow for the year.
Trilogy Metals Inc. (NYSE American: TMQ) Trilogy Metals reported a cash balance of $31.2 million as of August 31, 2026, with adjusted working capital of $30.3 million, and announced the closing of a $35.6 million strategic equity investment from the Department of War on September 11, 2026.
The company reported third quarter net income of $0.2 million compared to a net loss of $1.7 million a year earlier, while the nine-month period showed a net loss of $13.2 million versus a $7.5 million loss in the prior year period.
"The third quarter and the weeks that followed have been transformational for Trilogy Metals," said Tony Giardini, President and CEO. "With a defined permitting timeline, the investment by the U.S. Government, and a clear line of sight to a Record of Decision, Arctic is well positioned to become a cornerstone of a secure, domestic copper supply chain." Read the release.
Phillips Edison & Company, Inc. (Nasdaq: PECO) Phillips Edison & Company reaffirmed its full year 2026 earnings guidance and increased its gross acquisitions guidance to a range of $600 million to $700 million from $500 million to $600 million, after acquiring $459.7 million in assets and selling $174.0 million year to date through September 30, 2026.
The reaffirmed midpoint of full year 2026 Nareit FFO per diluted share guidance represents 6.3% year-over-year growth, while Core FFO guidance midpoint represents 6.2% growth and same-center NOI guidance midpoint represents 3.7% growth.
"We're pleased to reaffirm our guidance for full year 2026 Core FFO per share growth, which reflects 6.2% year-over-year growth at the midpoint," said Jeff Edison, Chairman and Chief Executive Officer. "We're able to do this while maintaining balance sheet strength and a disciplined approach to investing that have always defined PECO."
Axogen, Inc. (Nasdaq: AXGN) Axogen completed its acquisition of BioCircuit Technologies, adding NerveTape, which the company describes as the first FDA cleared device for sutureless peripheral nerve repair.
"NerveTape represents a new standard of care as the first sutureless nerve repair option, one that is simpler, faster, and more effective than microsuturing," said Michael Dale, President and Chief Executive Officer of Axogen.
The company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue, which was not included in Axogen's full-year 2026 guidance of at least 24% revenue growth. Axogen continues to expect gross margin of at least 73% and to be free cash positive for the full year.
Contact Information:
Media Contact: [email protected]
DISCLAIMER: Nothing in this article should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. This article is being distributed by Stock Preachers, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution, and MEL has no advertising or digital media agreement with any company mentioned in this article. The companies mentioned have not reviewed or approved this article. Market Equities and its owners, operators, directors, and affiliates may, from time to time, hold positions in securities mentioned in this article or in the broad-market index funds that track them, and reserve the right to buy, sell, or hold such securities at any time without further notice. Information in this article was obtained from sources believed to be reliable, including company news releases and public market data, but its accuracy cannot be guaranteed. Market data is as of the time stated and may be delayed. Portions of this commentary were produced with the assistance of automated tools from that data and reviewed against it. Investing in securities involves risk, including the possible loss of some or all of your investment. Technical analysis describes past price and volume behavior and does not predict future results; support and resistance levels can fail at any time. References to the companies named in this article are provided solely as market and sector context and as summaries of each company's own public news releases. No partnership, affiliation, or endorsement is implied, and nothing in this article is a recommendation to buy, sell, or hold any security. Quotations attributed to company executives are reproduced from those companies' own news releases. Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially. Readers should review each company's filings with the SEC and applicable Canadian securities regulators. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article. Eagle Eye is not a broker-dealer, and nothing it provides is investment advice. Data may be delayed. Always do your own research.
SOURCE Stock Preachers
Share this article